clinical trial · NCT04314531
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
Active Psoriatic ArthritisTILDmatching placebo injections
brief summary
This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .
started
Jul 1, 2020
primary completion
Jun 4, 2025
completion
Apr 1, 2026
last updated
Mar 10, 2026
official title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol